Understand the source comparison
Metabolism Boost Peptides 2026 Update: Clinical vs Consumer Access
Semaglutide (Ozempic/Wegovy) GLP-1 receptor agonist. Appetite suppression, gastric emptying delay 0–2% (weight-adjusted) Prescription (FDA-approved for obesity) Effective for weight loss via caloric reduction; does not increase basal metabolic rate Tirzepatide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Ozempic/Wegovy)
- GLP-1 receptor agonist. Appetite suppression, gastric emptying delay
- 0–2% (weight-adjusted)
- Prescription (FDA-approved for obesity)
- Effective for weight loss via caloric reduction; does not increase basal metabolic rate
- Tirzepatide (Mounjaro/Zepbound)
- GLP-1/GIP dual agonist. Appetite suppression, insulin sensitivity
- 0–3% (weight-adjusted)
- Prescription (FDA-approved)
- Superior weight loss to semaglutide; minimal direct metabolic rate enhancement
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist. GH/IGF-1 secretion, lean mass accrual
- 6–8%
- Research chemical (non-FDA-approved)
- Measurable BMR increase; appetite stimulation limits use in weight loss contexts
- MOTS-c
- AMPK activation. Mitochondrial biogenesis, fatty acid oxidation
- 12–18% (preclinical)
- Investigational only
- Strong preclinical metabolic effects; no human Phase 2 data as of 2026
- Survodutide
- GLP-1/glucagon dual agonist. Appetite suppression + thermogenesis
- 4–6%
- Phase 3 trials (investigational)
- Combines GLP-1 weight loss with mild glucagon-driven metabolic rate increase